<DOC>
	<DOC>NCT02678260</DOC>
	<brief_summary>The purpose of this study is to characterize the safety, tolerability, Pharmacokinetics (PK), and antitumor activity of PDR001 administered intravenous (i.v.) as a single agent to Japanese patients.</brief_summary>
	<brief_title>Phase I Study of PDR001 in Patients With Advanced Malignancies.</brief_title>
	<detailed_description />
	<mesh_term>Neoplasms</mesh_term>
	<criteria>Patients with advanced/metastatic solid tumors, with measurable or nonmeasurable disease as determined by response evaluation criteria in solid tumors (RECIST) version 1.1, who have progressed despite standard therapy or are intolerant of standard therapy, or for whom no standard therapy exists ECOG Performance Status â‰¤ 2 Active autoimmune disease Active hepatitis B virus (HBV) or hepatitis C virus (HCV) infection Prior PD1 or PDL1directed therapy Other protocol defined inclusion/exclusion may apply.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>Advanced malignancies</keyword>
	<keyword>PDR001</keyword>
	<keyword>Japanese patients</keyword>
	<keyword>adults</keyword>
</DOC>